Latest Report on Osteoarthritis Pain – Pipeline Review, H1 2020

Research By Markets adds Market Research Report - Latest Report on Osteoarthritis Pain – Pipeline Review, H1 2020

For detailed information: https://www.researchbymarkets.com/report/osteoarthritis-pain-pipeline-review-h1-2020-598531.html

Osteoarthritis Pain – Pipeline Review, H1 2020

Summary

Osteoarthritis Pain – Pipeline Review, H1 2020, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

Report Highlights

Osteoarthritis Pain – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 2, 1, 8, 21, 9, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
AbbVie Inc
Achelios Therapeutics Inc
AKL Research and Development Ltd
Ampio Pharmaceuticals Inc
Andros Pharmaceuticals Co Ltd
AntalGenics SL
Antibe Therapeutics Inc
Apimeds Inc
Aquilus Pharmaceuticals Inc
Arena Pharmaceuticals Inc
AstraZeneca Plc
Axsome Therapeutics Inc
BELLUS Health Inc
Calchan Ltd
Cara Therapeutics Inc
CDA Research Group Inc
Centrexion Therapeutics Corp
Chromocell Corp
Cmxtwenty
Concentric Analgesics Inc
Elite Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Flexion Therapeutics Inc
Futura Medical Plc
GlaxoSmithKline Plc
Grunenthal GmbH
Hisamitsu Pharmaceutical Co Inc
Iroko Pharmaceuticals LLC
Levicept Ltd
Mestex AG
Nuvo Pharmaceuticals Inc
Olatec Therapeutics LLC
OliPass Corporation
Ono Pharmaceutical Co Ltd
Peptide Logic LLC
Pfizer Inc
Pharmnovo AB
ProteoThera Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
Rottapharm Biotech Srl
Sansho Co Ltd
Shionogi & Co Ltd
Shulov Innovative Science Ltd
Sorrento Therapeutics Inc
Symic Bio Inc
Taiwan Liposome Co Ltd
Techfields Pharma Co Ltd
Vertex Pharmaceuticals Inc
Xalud Therapeutics Inc
Xenexus Pharmaceuticals Pty Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/598531

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.